Search research articles
Contact Us
Filters
Showing results (61-70 of 124) with videos related to
Page
of 13
Sort By:
The Journal of Gene Medicine
|
December 7, 2006
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity
Anna Kanerva, Mari Raki, Tuuli Ranki, et al.
Cancer Research
|
August 3, 2002
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors
Yosef S Haviv, Jerry L Blackwell, Anna Kanerva, et al.
Oncoimmunology
|
November 3, 2018
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
Sadia Zafar, Suvi Sorsa, Mikko Siurala, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 9, 2012
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer
Otto Hemminki, Iulia Diaconu, Vincenzo Cerullo, et al.
International Journal of Cancer
|
June 16, 2004
Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer
Gerd J Bauerschmitz, Anna Kanerva, Minghui Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 1, 2016
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
Mikko Siurala, Riikka Havunen, Dipongkor Saha, et al.
Human Gene Therapy
|
February 26, 2009
Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver
Iulia Diaconu, Laura Denby, Sari Pesonen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 4, 2006
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells
Gerd J Bauerschmitz, Kilian Guse, Anna Kanerva, et al.
Oncoimmunology
|
March 28, 2017
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy
Sadia Zafar, Suvi Parviainen, Mikko Siurala, et al.
Human Gene Therapy
|
January 24, 2019
Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs
Camilla Heiniö, Suvi Sorsa, Mikko Siurala, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 124) with videos related to
Sort By:
Page
of 13
The Journal of Gene Medicine
|
December 7, 2006
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity
Anna Kanerva, Mari Raki, Tuuli Ranki, et al.
Cancer Research
|
August 3, 2002
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors
Yosef S Haviv, Jerry L Blackwell, Anna Kanerva, et al.
Oncoimmunology
|
November 3, 2018
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
Sadia Zafar, Suvi Sorsa, Mikko Siurala, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 9, 2012
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer
Otto Hemminki, Iulia Diaconu, Vincenzo Cerullo, et al.
International Journal of Cancer
|
June 16, 2004
Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer
Gerd J Bauerschmitz, Anna Kanerva, Minghui Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 1, 2016
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
Mikko Siurala, Riikka Havunen, Dipongkor Saha, et al.
Human Gene Therapy
|
February 26, 2009
Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver
Iulia Diaconu, Laura Denby, Sari Pesonen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 4, 2006
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells
Gerd J Bauerschmitz, Kilian Guse, Anna Kanerva, et al.
Oncoimmunology
|
March 28, 2017
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy
Sadia Zafar, Suvi Parviainen, Mikko Siurala, et al.
Human Gene Therapy
|
January 24, 2019
Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs
Camilla Heiniö, Suvi Sorsa, Mikko Siurala, et al.
Page
of 13